A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

In fact, you may have gotten more than a few targeted ads on social media from telehealth platforms selling these cheaper GLP ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Hidden fat stored deep within muscles can significantly raise your risk of heart disease, heart attacks, and heart failure, ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...